^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Estybon (rigosertib) (PI3K inhibitor, PLK1 inhibitor, RAS antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

    Excerpt:
    ...- Have a histologically or cytologically confirmed diagnosis of Stage IV metastatic lung adenocarcinoma (AJCC version 8) with mutation analysis by next generation sequencing (NGS) confirming KRAS mutation either at time of diagnosis or at progression on first line treatment....
    Trial ID:
    NCT04263090
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onconova Therapeutics Inc Press Release
    Title:

    Onconova Therapeutics Provides An Update On The Phase 1/2a Trial Of Rigosertib-Nivolumab Combination In KRAS+ Non-Small Cell Lung Cancer

    Published date:
    06/28/2021
    Excerpt:
    Onconova Therapeutics, Inc...today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The clinical data to date provide preliminary evidence of potential anti-cancer activity of rigosertib-nivolumab combination therapy in advanced metastatic KRAS+ non-small cell lung cancer.
    Trial ID:
    NCT04263090